All In Biotech

Drug Trial Radar · NCT02481674

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease to Assess the Safety, Tolerability, pk, and Efficacy of Pepinemab

Last checked: Nov 19, 2026Latest source record: May 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 301 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

301

Actual

Start

Jul 2015

Primary completion

Aug 2020

Study completion Aug 2020

Sponsor

Lead sponsor
Vaccinex Inc.Industry
Sponsor type
Industry
Collaborators
Huntington Study Group
First posted
Jun 25, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of Pepinemab in subjects with late prodromal and early manifest Huntington's disease.

Conditions

  • Huntington's Disease

Interventions

  • VX15/2503Drug

    VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.

  • PlaceboDrug

    Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Revisions to SAP were made prior to un-blinding, on June 30, 2020, upon consultation with FDA.Time frame: Prior to DBL/Study Completion
  2. Safety and tolerability of monthly intravenous (IV) administration of pepinemab relative to placebo in subjects with early HD (Cohort B pooled, includes Cohort B1 Early Manifest and Cohort B2 Late Prodromal HD).Time frame: Up to 18 months
  3. Efficacy of monthly IV administration of pepinemab relative to placebo in Early Manifest HD (Cohort B1)Time frame: Up to 18 months

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California, San Diego

    La Jolla, California

  • University of California San Francisco

    San Francisco, California

  • University of Colorado - Denver

    Aurora, Colorado

  • Georgetown University

    Washington D.C., District of Columbia

  • University of Florida Gainesville

    Gainesville, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • University of Louisville

    Louisville, Kentucky

  • Johns Hopkins University

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Charlestown, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Washington University

    St Louis, Missouri

  • Columbia University

    New York, New York

  • Columbia University

    New York, New York

  • University of Rochester

    Rochester, New York

  • Duke University Health Center

    Durham, North Carolina

  • Wake Forest University

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Ohio State University

    Columbus, Ohio

  • University of Toledo

    Toledo, Ohio

  • Vanderbilt University

    Nashville, Tennessee

  • University of Texas Houston Medical School

    Houston, Texas

  • University of Vermont

    Burlington, Vermont

  • Virginia Commonwealth University

    Richmond, Virginia

  • University of Washington and VA Puget Sound Health Care System

    Seattle, Washington

  • University of Washington

    Seattle, Washington

  • University of Alberta

    Edmonton, Alberta, Canada

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • Centre hospitalier de l'Université de Montréal (CHUM)

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.